30.10
-0.34 (-1.12%)
| Previous Close | 30.44 |
| Open | 30.39 |
| Volume | 357,718 |
| Avg. Volume (3M) | 433,247 |
| Market Cap | 970,731,008 |
| Price / Earnings (TTM) | 12.86 |
| Price / Earnings (Forward) | 4.76 |
| Price / Sales | 2.30 |
| Price / Book | 4.15 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 - 24 Feb 2025 |
| Profit Margin | 14.78% |
| Operating Margin (TTM) | 35.17% |
| Diluted EPS (TTM) | 2.34 |
| Quarterly Revenue Growth (YOY) | 16.50% |
| Quarterly Earnings Growth (YOY) | -54.80% |
| Total Debt/Equity (MRQ) | 373.23% |
| Current Ratio (MRQ) | 0.970 |
| Operating Cash Flow (TTM) | 193.67 M |
| Levered Free Cash Flow (TTM) | 324.09 M |
| Return on Assets (TTM) | 9.67% |
| Return on Equity (TTM) | 42.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Collegium Pharmaceutical, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.50 |
|
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 1.64% |
| % Held by Institutions | 122.05% |
| 52 Weeks Range | ||
| Median | 37.00 (22.92%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 11 Oct 2024 | 37.00 (22.92%) | Hold | 37.72 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2024 | Announcement | Collegium to Participate in Upcoming Investor Conferences |
| 07 Nov 2024 | Announcement | Collegium Reports Record Third Quarter 2024 Financial Results |
| 07 Nov 2024 | Announcement | Collegium Appoints Vikram Karnani as Chief Executive Officer |
| 24 Oct 2024 | Announcement | Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |